In light of the fact that BRAF status in melanoma is a predictor of response to BRAF inhibitors, it would also be important to examine the expression and localization of PRMT5 in BRAF inhibitor-resistant versus inhibitor-sensitive cells, or in tumors which are or are not responsive to immunotherapy. The gene discussed is BRAF; the disease is melanoma.